ライフサイエンスコーパス: end-stage kidney disease

1 die prematurely than they are to progress to end stage kidney disease.

2 of renal replacement therapy for those with end-stage kidney disease.

3 rimary outcomes were all-cause mortality and end-stage kidney disease.

4 lly irreversible process causing chronic and end-stage kidney disease.

5 , were the most effective strategies against end-stage kidney disease.

6 hanism to delay the onset and progression of end-stage kidney disease.

7 interstitial fibrosis underlies all forms of end-stage kidney disease.

8 podocyte injury and promotes progression to end-stage kidney disease.

9 ion in the form of AKI, progressive CKD, and end-stage kidney disease.

10 total mortality, nonvascular mortality, and end-stage kidney disease.

11 protein requirements in patients with CKD or end-stage kidney disease.

12 y 3 wk after birth and progressed rapidly to end-stage kidney disease.

13 patients with atherosclerosis, diabetes, and end-stage kidney disease.

14 o prevent its development and progression to end-stage kidney disease.

15 nd, in steroid-resistant nephrotic syndrome, end-stage kidney disease.

16 causing early-onset nephrotic syndrome with end-stage kidney disease.

17 /min per 1.73 m(2) (stage 3 to 5), excluding end-stage kidney disease.

18 eight (LMW) proteinuria that can progress to end-stage kidney disease.

19 as "myeloma kidney" that often progresses to end-stage kidney diseases.

20 to 26]), total mortality (9% [-3 to 19]), or end-stage kidney disease (10% [-6 to 23]).

21 its definition (Risk, Injury, Failure, Loss, End-stage kidney disease, Acute Kidney Injury Network, a

22 a heightened risk of developing chronic and end-stage kidney disease, an association that is largely

23 ion may be associated with an excess risk of end-stage kidney disease and death.

24 ar calcification is common in the setting of end-stage kidney disease and is associated with increase

25 review current data on the global burden of end-stage kidney disease and the distribution of major r

26 ), and non-vascular and all-cause mortality, end-stage kidney disease, and adverse events, as well as

27 SRNS inevitably leads to end-stage kidney disease, and no curative treatment is a

28 Diabetic nephropathy is a major cause of end-stage kidney disease, and overactivity of the endoca

29 SGS), HIV-associated nephropathy (HIVAN) and end-stage kidney disease attributed to hypertension (H-E

30 The growing number of elderly patients with end-stage kidney disease awaiting transplantation has re

31 ant morbidity and mortality to patients with end-stage kidney disease but are resistant to therapy.

32 y transplantation is the optimal therapy for end-stage kidney disease but requires lifelong immunosup

33 Large numbers of patients with end-stage kidney disease caused by IgA nephropathy are t

34 defined by Risk, Injury, Failure, Loss, and End-stage kidney disease criteria and new need for renal

35 RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) criteria were used to assess s

36 nt of ammonia in the breath of patients with end-stage kidney disease demonstrated its significant re

37 sease (DKD) remains the most common cause of end-stage kidney disease despite multifactorial interven

38 study two variants in APOL1 associated with end-stage kidney disease discovered by admixture mapping

39 208 736 patients who initiated treatment for end-stage kidney disease during 2005-2008.

40 However, burden of end-stage kidney disease (ESKD) after pediatric LT has n

41 The adjusted rate of end-stage kidney disease (ESKD) among African Americans

42 ary care perspective emphasizing the risk of end-stage kidney disease (ESKD) and need for renal repla

43 k for type 2 diabetic (T2D) and non-diabetic end-stage kidney disease (ESKD) appear strong in African

44 Most children with end-stage kidney disease (ESKD) are treated with dialysi

45 The burden of end-stage kidney disease (ESKD) in sub-Saharan Africa is

46 on of proteinuric kidney diseases leading to end-stage kidney disease (ESKD), requiring renal replace

47 llion people worldwide are being treated for end-stage kidney disease (ESKD).

48 The increased burden of chronic kidney and end-stage kidney diseases (ESKD) in populations of Afric

49 sclerosis (FSGS) and hypertension-attributed end-stage kidney disease (H-ESKD) are associated with tw

50 r renal failure to an accepted treatment for end-stage kidney disease, heart disease, liver disease,

51 Although end-stage kidney disease in African Americans (AAs) is f

52 sease, is the most frequent genetic cause of end-stage kidney disease in children and young adults.

53 Review describes the incidence and causes of end-stage kidney disease in children on long-term dialys

54 epresents the most frequent genetic cause of end-stage kidney disease in the first three decades of l

55 disease is the leading cause of chronic and end-stage kidney disease in the United States and worldw

56 single most common cause of albuminuria and end-stage kidney disease in the United States.

57 e patients has transformed the management of end-stage kidney disease in this population.

58 universal transplantation as the therapy for end-stage kidney disease include the economic limitation

59 Rising numbers of patients reaching end-stage kidney disease intensify the demand for expans

60 End-stage kidney disease is a leading cause of morbidity

61 Treatment for end-stage kidney disease is a major economic challenge a

62 Children with end-stage kidney disease may have coexisting iatrogenic

63 (PBUTs) cause various deleterious effects in end-stage kidney disease patients, because their removal

64 n patients with type 1 diabetes mellitus and end-stage kidney disease prevents worsening of diabetic

65 and serious complication in individuals with end-stage kidney disease receiving peritoneal dialysis.

66 outcomes were kidney events (a composite of end-stage kidney disease, renal death, development of an

67 ine estimated glomerular filtration rate and end stage kidney disease requiring renal replacement the

68 lantation, and 400,000 individuals live with end-stage kidney disease requiring hemodialysis.

69 as meeting Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) Injury or Failure crite

70 here was no detectable effect on the risk of end-stage kidney disease (RR: 0.85; 95% CI: 0.49 to 1.49

71 ency, once established, tends to progress to end-stage kidney disease, suggesting some common mechani

72 s of kidney transplantation as a therapy for end-stage kidney disease that surpasses dialysis treatme

73 lerability may be a problem in patients with end-stage kidney disease.The impact of HCV infection on

74 n of modifiable risk factors for chronic and end-stage kidney disease to low- and middle-income count

75 rt study with 127 AA and white patients with end-stage kidney disease undergoing evaluation for KT (D

76 SRNS causes end-stage kidney disease, which cannot be cured.

77 ommend follow-up and treatment.Patients with end-stage kidney disease without cirrhosis and selected

78 With the rising prevalence of end-stage kidney disease worldwide, the proportion of th